Eisai to Unveil New Research on Lecanemab for Early Alzheimer’s Treatment at AAN 2026 Eisai is set to present groundbreaking findings on the treatment of early Alzheimer’s disease using Lecanemab at the AAN 2026 Annual Meeting, enhancing care pathways.

Eisai to Unveil New Research on Lecanemab for Early Alzheimer’s Treatment at AAN 2026 #Eisai #Leqembi #Alzheimer’s_Disease

Eisai unveils digital platform for kidney cancer patients Eisai has launched a 'digital destination', called Kompass, that aims to support patients after they have been given a diagnosis of kidney cancer.

#Eisai #digitalplatform #kidneycancerpatients #kidneycancer #digitaldestination #Kompass #kidneycancerdiagnosis #KidneyCancerKompass #patientorganisations #KCCure #KidneyCAN #KidneyCancerAssociation #NationalKidneyFoundation #Lenvima #lenvatinib #MSD #renalcellcarcinoma #RCC
zurl.co/qpSNo

NICE to reconsider two Alzheimer’s drugs, following manufacturers' appeal Two pioneering drugs that treat the underlying causes of Alzheimer's disease are to be reconsidered by NICE.

NICE to reconsider two Alzheimer’s drugs, following manufacturers' appeal

Read it here 👉️ buff.ly/Yz91dLW

#alzheimers #NICE #drug #appeal #Eisai #EliLilly

Register Login Page This site is intended for health professionals only

NICE to reconsider two Alzheimer’s drugs, following manufacturers’ appeal

Read it here 👉️ buff.ly/6W7tKLU

#Alzheimer #drug #treatment #Eisai #EliLilly

Eisai and Nuvation Bio's Taletrectinib Secures EMA Validation for Lung Cancer Treatment Eisai and Nuvation Bio announce the validation of Taletrectinib's Marketing Authorisation Application by the EMA for treating lung cancer, promising advances in therapy.

Eisai and Nuvation Bio's Taletrectinib Secures EMA Validation for Lung Cancer Treatment #Japan #Tokyo #Eisai #Nuvation_Bio #Taletrectinib

Eisai Launches Phase 2 Clinical Trial for Narcolepsy Treatment E2086 Eisai Inc. has commenced patient enrollment for a groundbreaking Phase 2 study evaluating E2086, a novel treatment for narcolepsy. This research aims to explore its efficacy, safety, and tolerability.

Eisai Launches Phase 2 Clinical Trial for Narcolepsy Treatment E2086 #United_States #Eisai #Nutley #Narcolepsy #E2086

Starting a New Era in Brain Health Management with Eisai's "Nou KNOW" via Smart Dock Yukaria's Smart Dock has launched Eisai's "Nou KNOW" brain health self-check tool, enhancing mental health evaluations effective March 2026.

Starting a New Era in Brain Health Management with Eisai's "Nou KNOW" via Smart Dock #Japan #Tokyo #Eisai #Yukaria #Nou_KNOW

New Insights on Lecanemab Emerge at the 2026 AD/PD™ Conference for Alzheimer’s Treatment Recent data presented at the 2026 AD/PD™ congress highlights the effectiveness of lecanemab in long-term Alzheimer's treatment, showing promising patient adherence.

New Insights on Lecanemab Emerge at the 2026 AD/PD™ Conference for Alzheimer’s Treatment #Sweden #Stockholm #Lecanemab #Eisai #BioArctic

New Insights on Long-Term Efficacy of Lecanemab Presented at 2026 AD/PD Congress At the 2026 AD/PD congress, BioArctic and Eisai unveiled significant findings on the long-term usage of lecanemab for Alzheimer's treatment, highlighting patient adherence.

New Insights on Long-Term Efficacy of Lecanemab Presented at 2026 AD/PD Congress #Sweden #Copenhagen #Lecanemab #Eisai #BioArctic

Unveiling Long-Term Benefits of LEQEMBI® in Alzheimer's Treatment: Real-World Insights New findings on LEQEMBI® reveal impressive long-term treatment persistence among patients, showcasing its effectiveness in Alzheimer's care.

Unveiling Long-Term Benefits of LEQEMBI® in Alzheimer's Treatment: Real-World Insights #USA #Cambridge #Eisai #Biogen #LEQEMBI®

How Eisai and EYSC Are Revolutionizing Human Capital Disclosure Strategies Discover how Eisai and EYSC are transforming human capital disclosure and leading to sustainable value creation through comprehensive strategies.

How Eisai and EYSC Are Revolutionizing Human Capital Disclosure Strategies #Japan #Tokyo #Eisai #Human_Capital #EYSC

Eisai joins with Pokémon for sleep awareness drive Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon Sleep.

#Eisai has launched a #campaign to raise awareness of #sleep disorders in #Japan, via a #partnership with #smartphone app #PokémonSleep.

Eisai to Unveil New Findings on Lecanemab at AD/PD™ 2026 Congress in Copenhagen Eisai will present the latest data on lecanemab, a groundbreaking treatment for Alzheimer's, during the AD/PD™ 2026 congress, held in Copenhagen.

Eisai to Unveil New Findings on Lecanemab at AD/PD™ 2026 Congress in Copenhagen #Lecanemab #Eisai #Alzheimer's

Presentation of Long-Term Lecanemab Treatment Data at AD/PD 2026 Congress BioArctic's partner Eisai will unveil pivotal long-term data on lecanemab at the AD/PD 2026 congress, detailing its efficacy and safety in treating Alzheimer's disease.

Presentation of Long-Term Lecanemab Treatment Data at AD/PD 2026 Congress #Sweden #Copenhagen #Lecanemab #Eisai #BioArctic

Eisai to Unveil Long-Term Insights on Lecanemab during AD/PD 2026 Conference Eisai will showcase important new data on lecanemab's long-term effects at the AD/PD™ 2026 conference, highlighting real-world treatment outcomes.

Eisai to Unveil Long-Term Insights on Lecanemab during AD/PD 2026 Conference #Japan #Tokyo #Lecanemab #Eisai #Leqembi

Eisai unveils digital platform for kidney cancer patients Eisai has launched a 'digital destination', called Kompass, that aims to support patients after they have been given a diagnosis of kidney cancer.

#Eisai has launched a 'digital destination', called #Kompass, that aims to support #patients after they have been given a #diagnosis of #kidneycancer.

BioArctic's Leqembi® Receives Priority Review for New Subcutaneous Formulation in China Leqembi® (lecanemab) has been granted Priority Review status for its subcutaneous formulation by China's NMPA. This could transform treatment options for Alzheimer's patients.

BioArctic's Leqembi® Receives Priority Review for New Subcutaneous Formulation in China #China #Beijing #Eisai #Leqembi #BioArctic

Leqembi® Achieves Major Sales Milestone of 20.7 Billion Yen in Q4 2025 Leqembi® generated impressive sales of 20.7 billion yen in the fourth quarter of 2025, marking a significant increase and highlighting its market strength.

Leqembi® Achieves Major Sales Milestone of 20.7 Billion Yen in Q4 2025 #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Leqembi® Sales Surge to 20.7 Billion Yen in Q4 2025 Amidst Collaboration Success Leqembi® has reported remarkable sales of 20.7 billion yen in Q4 2025, showcasing significant growth amid BioArctic and Eisai’s collaboration efforts.

Leqembi® Sales Surge to 20.7 Billion Yen in Q4 2025 Amidst Collaboration Success #Sweden #Stockholm #Eisai #Leqembi #BioArctic

Eisai and Henlius Secure Exclusive Agreement for Serplulimab in Japan Eisai and Henlius have announced a groundbreaking exclusive licensing deal for the anti-PD-1 antibody Serplulimab in Japan. This agreement is set to enhance cancer treatment options in the region.

Eisai and Henlius Secure Exclusive Agreement for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Strike Exclusive Deal for Serplulimab in Japan Eisai Co. and Henlius Biotech have reached a significant licensing agreement to commercialize the novel anti-PD-1 antibody serplulimab in Japan, enhancing cancer treatment options.

Eisai and Henlius Strike Exclusive Deal for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Join Forces for Innovative Cancer Treatment in Japan Eisai and Henlius have announced a commercial agreement for the anti-PD-1 antibody serplulimab, enhancing cancer treatment options in Japan.

Eisai and Henlius Join Forces for Innovative Cancer Treatment in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Forge Licensing Deal for Serplulimab in Japan Eisai and Henlius have signed an exclusive agreement for the commercialization of the anti-PD-1 drug Serplulimab in Japan, enhancing cancer treatment options.

Eisai and Henlius Forge Licensing Deal for Serplulimab in Japan #Japan #Tokyo #Eisai #Henlius #Serplulimab

Eisai and Henlius Collaborate to Bring Serplulimab to Japanese Patients Eisai and Henlius announce a partnership to exclusively commercialize Serplulimab in Japan, a groundbreaking anti-PD-1 antibody targeting unmet medical needs.

Eisai and Henlius Collaborate to Bring Serplulimab to Japanese Patients #Japan #Tokyo #Eisai #Henlius #Serplulimab

Pharma has varying levels of success developing drugs. That's a boon for biotech

Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022

$AMGN, $NVO, #Eisai top the list
$GSK, #Astellas, $ABBV are at the bottom

#learnbiotechinvesting #BiotechPrometheus

New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits - AktieGo BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI ...

Eisai and Biogen are developing a new version of their Alzheimer’s drug, LEQEMBI IQLIK, that patients could inject at home. The FDA has accepted it for Priority Review, with a decision expected in May 2026.

aktiego.com/new-leqembi-...

#Alzheimers #Healthcare #Biogen #Eisai #Pharma

Eisai Submits New Marketing Application for Leqembi® with Extended Dosing Schedule Eisai has submitted a Marketing Authorisation Variation to EMA for Leqembi® to allow intravenous maintenance dosing every four weeks, enhancing treatment options.

Eisai Submits New Marketing Application for Leqembi® with Extended Dosing Schedule #Eisai #Leqembi #BioArctic

Leqembi Iqlik Receives Priority Review for Subcutaneous Treatment by FDA The FDA has granted Priority Review to Eisai's supplemental Biologics License Application for Leqembi Iqlik, enabling at-home treatment for early Alzheimer's patients.

Leqembi Iqlik Receives Priority Review for Subcutaneous Treatment by FDA #USA #Stockholm #Eisai #Alzheimer's_Disease #LEQEMBI_IQLIK

Eisai's Leqembi Iqlik Gets Priority Review for Home Injection in Alzheimer's Treatment Eisai announces that the FDA has granted Priority Review for the subcutaneous form of Leqembi Iqlik, enabling at-home treatments for Alzheimer's.

Eisai's Leqembi Iqlik Gets Priority Review for Home Injection in Alzheimer's Treatment #USA #Stockholm #Eisai #Leqembi #IQLIK

FDA Accepts LEQEMBI IQLIK for At-Home Alzheimer's Treatment The FDA has accepted Eisai and Biogen's LEQEMBI IQLIK application for Alzheimer’s, offering a subcutaneous option for patients. A decision is due by May 2026.

FDA Accepts LEQEMBI IQLIK for At-Home Alzheimer's Treatment #United_States #Cambridge #Eisai #Leqembi #Alzheimer's_Disease